aka Mounjaro · Zepbound · LY3298176
Open any panel for the full data
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Approved by the FDA in 2022 for T2DM and 2023 for obesity, it represents the first dual incretin therapy. The SURPASS clinical program demonstrated superior glycemic control and weight loss compared to semaglutide in head-to-head trials.
Third-party creator videos and discussion, surfaced for research context. Amino Axiom does not endorse creator claims.
Tirzepatide to Retatrutide: The Mistake Everyone Makes - Dr Trevor Bachmeyer
Doctor’s WARNING: The Dark Side of GLP-1 Weight Loss (Is Retatrutide WORSE Than Tirzepatide?)
Your hunger is gone. You can go hours without thinking about food… Then 8pm hits. You’re stressed… and suddenly you’re in the pantry 😐 Soun
your GLP-1 results will stall without this one thing 👇 resistance training 💪 not walking not yoga not “staying active” lifting heavy thing
I need you to hear this 👇 if you’ve been told your whole life that you just need more discipline, more willpower, more motivation — that wa